The nonprofit ALS Association (ALSA) recently reflected on the successes its stakeholders achieved this year, ranging from access to specialized equipment and fundraising efforts to legislative advocacy work on Capitol Hill.
Dr. Veronique Belzil, an associate professor at Mayo Clinic College of Medicine in Jacksonville, Florida, recently discovered "new ALS genes and disease pathways" that can help in the creation of treatments for the disease, the ALS Association reported on its blog.
Tracking the body’s own immune response to ALS, also known as Lou Gehrig's disease, may give doctors new clues about the disease’s progression, according to a paper published in the July issue of the Journal of Neuroinflammation.
The ALS Association has joined the Muscular Dystrophy Association and the Les Turner ALS Foundation in opposing a plan that would eliminate federal funding for the Centers for Disease Control and Prevention's National ALS Registry.
A bill to eliminate the five-month waiting period for Social Security Disability Insurance (SSDI) for people living with amyotrophic lateral sclerosis (ALS) “can mean the difference between life and death,” the president of the ALS Association said recently.
Washington, D.C.’s ALS Association recently announced what it considers to be ten of the past year’s most outstanding advances in ALS research via its blog, citing substantial progress in studies, clinical trials and cooperative efforts.
Five finalists for the $400,000 ALS Assistive Technology Challenge prize were recently announced in Washington, D.C., bringing the competition a step closer to its final phase when a single winner prevails Dec. 5 in Dublin.
The ALS Association recently pledged a $2 million contribution aimed at augmenting the work of its ALS ONE-Massachusetts ALS Partnership (MAP), a new coalition of four aligned specialty health care organizations.
Embarking on a pioneering clinical trial, researchers at Los Angeles-based Cedars-Sinai Medical Center recently obtained authorization from the U.S. Food and Drug Administration (FDA) to test a new therapeutic approach to amyotrophic lateral sclerosis (ALS).